Long-term protection against carriage of hepatitis B virus after infant vaccination

Journal of Infectious Diseases

Volumn 193, Issue 11, 2006, Pages 1528-1535

  Van Der Sande, Marianne A B ^a,c   Waight, P ^a,d   Mendy, M ^a   Rayco Solon, P ^a,b   Hutt, P ^a   Fulford, T ^b   Doherty, C ^a   McConkey, S J ^a,e   Jeffries, D ^a   Hall, A J ^b   Whittle, H C ^a  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ENGERIX; EUVAX; HEPACINE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CHILD; CHILD CARE; CONTROLLED STUDY; DRUG EFFICACY; GAMBIA; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PREVALENCE; PRIORITY JOURNAL; SEROLOGY; VACCINATION; VACCINE FAILURE; VIRUS CARRIER; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGE FACTORS; CARRIER STATE; CHILD; CHILD, PRESCHOOL; GAMBIA; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; INFANT;

EID: 33646903917     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/503433     Document Type: Article

References (31)

1. World Health Organization. Hepatitis B fact sheet. Revised October 2000. Available at: http://www.who.int/mediacentre/factsheets/fs204. Last accessed 4 July 2005.
2. Bah E, Parkin DM, Hall AJ, Jack AD, Whittle H. Cancer in the Gambia: 1988-97. Br J Cancer 2001; 84:1207-14.
3. Harbarth S, Szucs T, Berger K, Jilg W. The economic burden of hepatitis B in Germany. Eur J Epidemiol 2000; 16:173-7.
4. Barin F, Perrin J, Chotard J, et al. Cross-sectional and longitudinal epidemiology of hepatitis B in Senegal. Prog Med Virol 1981; 27:148-62.
5. Chotard J, Inskip HM, Hall AJ, et al. The Gambia Hepatitis Intervention Study: follow up of a cohort of children vaccinated against hepatitis B. J Infect Dis 1992; 166:764-8.
6. Coursaget P, Leboulleux D, Soumare M, et al. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J Hepatol 1994; 21:250-4.
7. Resti M, Azzari C, Mannelli F, Rossi ME, Lionetti P, Vierucci A. Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated? Vaccine 1997; 15:1338-40.
8. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population-results of a 10-year study. J Infect Dis 1997; 175:674-7.
9. Viviani S, Jack A, Hall AJ, et al. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 1999; 17:2946-50.
10. Liao S, Li R, Li H, et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine 1999; 17:2661-6.
11. Chadha MS, Arankalle VA. Ten-year serological follow up of hepatitis B vaccine recipients. Indian J Gastroenterol 2000; 19:168-71.
12. Poovorawan Y, Theamboonlers A, Hirsch P, et al. Persistence of antibodies to the surface antigen of the hepatitis B virus in children subjected to the Expanded Programme on Immunization, including hepatitis-B vaccine, in Thailand. Ann Trop Med Parasitol 2000; 94:615-21.
13. McMahon BJ, Bruden DL, Peterson KM, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005; 142:333-41.
14. Yen MF, Lim WL, Chan AO, Wong DK, Sum SS, Lai CL. 18-year follow-up study of a prospective randomised trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol 2004; 2:941-5.
15. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2000; 19:877-85.
16. FitzSimons D, Francois G, Hall A, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005; 23:4158-66.
17. Lu CY, Chiang BL, Chi WK, et al. Waning immunity to plasma/derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004; 40:1415-20.
18. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 1993; 253:197-201.
19. Whittle HC, Bradley AK, McLauchlen K, et al. Hepatitis B virus infection in two Gambian villages. Lancet 1983; 1:1203-6.
20. Whittle H, Inskip H, Bradley AK, et al. The pattern of childhood hepatitis B infection in two Gambian villages. J Infect Dis 1990; 161:1112-5.
21. Whittle HC, Inskip H, Hall AJ, Mendy M, Downes R, Hoare S. Vaccination against hepatitis B and protection against chronic viral carriage in The Gambia. Lancet 1991; 337:747-50.
22. Whittle HC, Maine N, Pilkington J, et al. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 1995; 345:1089-92.
23. Whittle HC, Jaffar S, Wansborough M, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002; 325:569-72.
24. Fortuin M, Karthigesu V, Allison L, et al. Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J Infect Dis 1994; 169:1374-6.
25. Jack AD, Hall AD, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? J Infect Dis 1999; 179:489-92.
26. Whittle H, Aaby P, Samb B, et al. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa. Lancet 1999; 353:98-102.
27. Edmunds WJ, Medley GF, Nokes DJ, O'Callaghan CJ, Whittle HC, Hall AJ. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect 1996; 117:313-25.
28. Medley GF, Lindop NA, Edmunds WJ, Nokes DJ. Hepatitis-B virus endemicity: heterogeneity, catastrophic dynamics and control. Nat Med 2001; 7:619-24.
29. Fortuin M, Chotard J, Jack AD, et al. Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation. Lancet 1993; 341:1129-31.
30. Petersen KM, Bulkow LR, McMahon BJ, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J 2004; 23:650-5.
31. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355:561-5.